ArticleCureus2026
Endometrial Neuroendocrine Carcinoma With Widespread Metastases: Diagnostic and Therapeutic Challenges in a Rare Malignancy.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Endometrial neuroendocrine carcinomas (NECs) are rare, aggressive malignancies with early metastatic potential and poor prognosis. We present the case of a 54-year-old woman who presented with thoracic back pain and lower extremity paresthesia. Imaging revealed a T1 compression fracture, additional spinal metastases, liver and lung lesions, a thickened endometrium, and a left adnexal mass. Tumor markers, including CA-125, CA 19-9, and CEA, were markedly elevated. Thoracic spine MRI confirmed spinal stenosis and metastatic involvement. She underwent urgent T1 laminectomy with C5-T3 fusion, followed by systemic therapy with carboplatin/paclitaxel plus pembrolizumab, and later transitioned to carboplatin/etoposide. Treatment was complicated by
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.